The 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA, a small non-coding RNA molecule that plays a crucial Read more about C. elegans scientists awarded 2014 Nobel Prize in Medicine for their pioneering work discovering microRNA[…]
vivoVerse is excited to announce it has been awarded a Phase I SBIR grant from the National Institute of Environmental Health Sciences (NIEHS) for the continued development of the company’s Read more about vivoVerse awarded NIH/NIEHS grant to develop novel approaches for developmental neurotoxicity testing[…]
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $1.83M Phase II SBIR grant from the National Institute of Environmental Health Sciences (NIEHS) for the Read more about vivoVerse awarded SBIR Phase II grant from the NIEHS[…]
vivoVerse cofounders Dr. Adela Ben-Yakar and Dr. Sudip Mondal have published an article in Nature Methods titled “Femtosecond laser microdissection for isolation of regenerating C. elegans neurons for single-cell RNA sequencing.” This publication from their Read more about vivoVerse cofounders publish single-cell isolation method using femtosecond laser microdissection (fs-LM)[…]
The 2023 Society of Toxicology (SOT) Annual Meeting is coming up this month, and we will be attending! The SOT Annual Meeting is one of the largest gatherings of toxicologists Read more about vivoVerse at the Society of Toxicology Annual Meeting in Nashville[…]
vivoVerse (formerly operating as Newormics) has expanded its base of operations into a customized, newly refurbished space in Austin, Texas. The new headquarters comprises over 2400 square-foot of laboratory, office, Read more about vivoVerse moves into new HQ[…]
Dear Colleagues, Customers, and Collaborators: At our Newormics location in Austin, TX, we have been allowed to re-open. We have resumed operations in our lab and in our manufacturing facility Read more about Newormics resumes operations[…]
Patent covers the vivoChip® invention that vivoVerse licensed for use in immobilization of C. elegans for high resolution imaging. AUSTIN, TX. August 5, 2020 – vivoVerse (formerly operating as Newormics), a developer of Read more about vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office[…]
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) Read more about vivoVerse awarded SBIR Phase II grant from the NIMH[…]
Dear Customers, Colleagues, and Collaborators: At Newormics, we recognize that combating the spread of this new virus requires a global community effort. As we navigate this uncharted landscape together with Read more about COVID-19 UPDATE[…]
Dr. Sudip Mondal has a Ph.D. in Physics and several years of postdoctoral research experience in neuroscience and microfluidics-based screening tools. He has developed several technologies that have translated to the market. One of his recent works at The University of Texas at Austin involved a high-throughput screening platform with C. elegans model systems, which is commercialized by vivoVerse. As a Director of Science, Sudip is responsible for developing new technologies and innovative assays to increase the vivoVerse product & service portfolio.
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC, now vivoVerse. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at vivoVerse, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben-Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben-Yakar began the research that has culminated in the launch of vivoVerse (formerly Newormics)